1. Home
  2. CUE vs CEE Comparison

CUE vs CEE Comparison

Compare CUE & CEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • CEE
  • Stock Information
  • Founded
  • CUE 2014
  • CEE 1990
  • Country
  • CUE United States
  • CEE Germany
  • Employees
  • CUE N/A
  • CEE N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • CEE Finance Companies
  • Sector
  • CUE Health Care
  • CEE Finance
  • Exchange
  • CUE Nasdaq
  • CEE Nasdaq
  • Market Cap
  • CUE 64.4M
  • CEE 68.6M
  • IPO Year
  • CUE 2018
  • CEE N/A
  • Fundamental
  • Price
  • CUE $1.25
  • CEE $11.80
  • Analyst Decision
  • CUE Strong Buy
  • CEE
  • Analyst Count
  • CUE 5
  • CEE 0
  • Target Price
  • CUE $5.00
  • CEE N/A
  • AVG Volume (30 Days)
  • CUE 971.4K
  • CEE 22.0K
  • Earning Date
  • CUE 11-14-2024
  • CEE 01-01-0001
  • Dividend Yield
  • CUE N/A
  • CEE 3.86%
  • EPS Growth
  • CUE N/A
  • CEE N/A
  • EPS
  • CUE N/A
  • CEE N/A
  • Revenue
  • CUE $9,532,000.00
  • CEE N/A
  • Revenue This Year
  • CUE $104.81
  • CEE N/A
  • Revenue Next Year
  • CUE N/A
  • CEE N/A
  • P/E Ratio
  • CUE N/A
  • CEE N/A
  • Revenue Growth
  • CUE 149.53
  • CEE N/A
  • 52 Week Low
  • CUE $0.45
  • CEE $7.80
  • 52 Week High
  • CUE $3.25
  • CEE $10.32
  • Technical
  • Relative Strength Index (RSI)
  • CUE 43.10
  • CEE 57.34
  • Support Level
  • CUE $1.32
  • CEE $10.60
  • Resistance Level
  • CUE $1.99
  • CEE $13.36
  • Average True Range (ATR)
  • CUE 0.29
  • CEE 0.43
  • MACD
  • CUE -0.06
  • CEE 0.11
  • Stochastic Oscillator
  • CUE 0.67
  • CEE 44.09

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About CEE The Central and Eastern Europe Fund Inc. (The)

CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.

Share on Social Networks: